ReviewBiology open2026
Not just fillers: the emerging role of bone marrow adipocytes in bone and bone marrow homeostasis.
Review in Biology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone marrow adipose tissue (BMAT) is a phylogenetically conserved fat depot occupying a substantial fraction of the medullary cavity in vertebrates, yet its functional significance has only recently begun to be appreciated. Long dismissed as an inert filler, BMAT is now recognized as a dynamic and metabolically active compartment participating in the regulation of bone remodeling and hematopoiesis. Bone marrow adipocytes (BMAds) originate from skeletal stem cells (SSCs) and are anatomically and functionally distinct from peripheral white adipocytes, exhibiting a unique lipid metabolism and reduced lipolytic responsiveness under basal conditions. Two spatially and functionally distinct BMAT subtypes, i.e. regulated (rBMAT) and constitutive (cBMAT), respond differently to physiological and pathological stimuli, including caloric restriction, cold exposure, irradiation, and disease. BMAT expands in conditions such as osteoporosis and aging, while contracting in the context of bone metastasis and hematological malignancies, underscoring its tight coupling to the marrow microenvironment. Mechanistically, BMAT regulates bone remodeling by expressing osteoclastogenic factors and through lipid-mediated paracrine signaling, and supports or restrains hematopoietic stem cells, depending on context and skeletal site, by secreting key molecules in the hematopoietic niche. Emerging evidence from genome-wide Mendelian randomization studies now establishes a causal link between elevated BMAT and osteoporosis risk in humans. In the oncological setting, BMAds fuel tumor cell metabolism, promote cancer cell migration and chemoresistance, and remodel the marrow niche to favor malignant progression. This article critically reviews the current understanding of BMAT biology, from its anatomical organization and developmental origins to its roles in skeletal and hematopoietic homeostasis.
Indexed as
Identifiers
42770526What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.